For Recurrent Bacterial Vaginosis, Simplified Once-Weekly Treatment Found More Effective than CDC-Recommended Regimen
Secnidazole granules reduced recurrence rates to 20% over a period of 28 weeks in a small prospective pilot study, outperforming cumbersome daily regimens.
Cannabis-Related ED Visits May Raise Dementia Risk: Daily Dose
Your daily dose of the clinical news you may have missed.
Evidence for Adverse Effects of High-Dose GC Treatment of Congenital Adrenal Hyperplasia Broadened, Deepened in New Literature Review
The most commonly reported adverse effects of high-dose glucocorticoid therapy were on bone health, cardiometabolic function, and height and growth.
ACOG 2025: Menopause and Vasomotor Symptoms Preview
A preview of sessions covering menopause and vasomotor symptoms during ACOG 2025 in Minneapolis, MN.
Oral Gepotidacin Rivals Standard Gonorrhea Regimen in Trial: Daily Dose
Atopic Dermatitis Treatment Caution: Long-Term Oral Corticosteroid Use Ups Cardiovascular and Thrombotic Risks
The potential cardiovascular impact of prolonged oral corticosteroid therapy in the AD population observed in this study confirms longstanding cautions.
Semaglutide Linked to Reduced Risk for MACE Months Before Weight Loss Begins: Post Hoc Analysis
Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.
Bone Loss Slowed in Women on Med Diet, Exercise Plan: Daily Dose
Managing Vasomotor Symptoms of Menopause: A Topline Comparison of Treatments
Medical and nonpharmacologic treatment options for VMS range in efficacy and risk/benefit profile; a short slide show offers a topline look at how many compare.
Vasomotor Symptoms of Menopause: Facts At-a-Glance for Primary Care
Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.
A Half Dose of Semaglutide Yields Weight Loss Equivalent to Clinical Trial Doses in Combination with Online Support Program
Semaglutide dosing was individually tailored for adults with obesity and supported with app-based coaching on diet, physical activity, and other lifestyle factors.
FDA Clears STS101 Nasal Powder for Acute Treatment of Migraine: Daily Dose
FDA Approves First At-Home Pap Smear Alternative for Cervical Cancer Screening, from Teal Health
The Teal Wand allows women to collect a vaginal sample in the privacy of their home and, according to Teal Health, the test has 96% accuracy for cervical precancer.
Tirzepatide Demonstrates Greater Weight Loss Than Semaglutide in Head-to-Head Study
Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.
Novel TK1 Inhibitor Demonstrates Rapid, Dose-Dependent Efficacy in Atopic Dermatitis in Ph 1 Trial
Adults receiving the highest dose achieved 2 times the reduction in EASI scores vs placebo with responses emerging as early as day 8 of treatment.
Genetic Risk Score Identifies Individuals Likely to Report Adverse Events from GLP-1 Mimetic Therapy
The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.
Tirzepatide Associated with Improved HF Symptoms, Renal Function in People with Obesity, CKD: Daily Dose
LEO Pharma Announces Positive Preliminary Phase 2b Findings for Temtokibart in Atopic Dermatitis
The IL-22FA1 antagonist achieved positive outcomes for the primary endpoint based on percentage change in EASI from baseline to week 16 for 3 highest doses, according to LEO.
Crinecerfont Reduces GC Dosing, Improves Androstenedione Levels Across Multiple Pediatric Subgroups
Data for GC reduction and improved A4 levels were consistent across subgroups stratified by sex, race, age, BMI, and baseline A4 levels, according to Neurocrine Biosciences.
Cervical Cancer Screening Best Practices for Physicians
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.
.JPG%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Semaglutide Linked to Reduced Risk for MACE Months Before Weight Loss Begins: Post Hoc Analysis / image credit Jorge Plutzky, MD, Brigham and Women's Hospital")
